Position statement on doxycycline post-exposure prophylaxis for the prevention of bacterial sexually transmissible infections in Aotearoa New Zealand: the New Zealand Sexual Health Society
Julia Scott
A B , Massimo Giola A C and Jeannie Oliphant A D *
A
B
C
D
Abstract
Recent studies have demonstrated that doxycycline post-exposure prophylaxis (doxy-PEP) reduces the risk of syphilis and chlamydia in men who have sex with men and transgender women who have sex with men who are at risk of sexually transmitted infections (STIs). With several international organisations publishing guidance regarding doxy-PEP use, and substantial community and sector interest, the New Zealand Sexual Health Society drafted an interim statement and then convened a cross-sectoral meeting to discuss doxy-PEP benefits and risks, and review and revise the statement. There was strong agreement that doxy-PEP be considered as part of a comprehensive STI prevention approach to people assigned male sex at birth who have sex with men who are at risk of syphilis, primarily as an intervention to prevent syphilis. New Zealand Sexual Health Society advises that doxy-PEP be proactively offered to people assigned male sex at birth who have sex with men with a diagnosis of syphilis or two other bacterial STIs in the past 12 months, and considered for others as outlined in the statement. Prescription of doxy-PEP should include counselling on the benefits and harms including side-effects and antimicrobial resistance, with users assisted to maximise the benefits of doxy-PEP while minimising overall antibiotic use. STI diagnostic considerations, and monitoring and surveillance are discussed.
Keywords: doxycycline, New Zealand, prevention, STIs, syphilis.
References
1 The Institute of Environmental Science and Research Ltd (ESR). Sexually Transmitted Infections in New Zealand: Supplementary Annual Surveillance Report 2023. Porirua, New Zealand: The Institute of Environmental Science and Research Ltd (ESR); 2024. Available at https://www.esr.cri.nz/digital-library/sexually-transmitted-infections-supplementary-annual-surveillance-report-2023/
2 Molina J-M, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 18(3): 308-317.
| Crossref | Google Scholar | PubMed |
3 Molina J-M, Bercot B, Assoumou L, Michele I, Rubenstein E, Pialoux G, et al., editors. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP. 30th Conference on Retroviruses and Opportunistic Infections (CROI); 2023. Available at https://www.croiconference.org/wp-content/uploads/sites/2/resources/2023/croi2023-abstract-ebook-v2.pdf
4 Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023; 388(14): 1296-306.
| Crossref | Google Scholar | PubMed |
5 Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, et al. Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med 2023; 389(25): 2331-40.
| Crossref | Google Scholar | PubMed |
6 Cornelisse VJ, Riley B, Medland NA. Australian consensus statement on doxycycline post-exposure prophylaxis (doxy-PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men. Med J Aust 2024; 220(7): 381-6.
| Crossref | Google Scholar | PubMed |
7 Bachmann LH, Barbee LA, Chan P, et al. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep 2024; 73: 1-8.
| Crossref | Google Scholar |
8 New York State Department of Health AIDS Institute (NYSDOH AI). Doxycycline Post-Exposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections; 2023. Available at https://www.ncbi.nlm.nih.gov/books/NBK597440/
9 California Department of Public Health (CDPH). Doxycycline post-exposure prophylaxis (doxy-PEP) for the prevention of bacterial sexually transmitted infections (STIs); 2023. Available at https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CDPH-Doxy-PEP-Recommendations-for-Prevention-of-STIs.pdf
10 British Columbia Centre for Excellence in HIV/AIDS. Therapeutic Guidelines for Opportunistic Infections: Syphilis; 2023. Available at https://www.bccfe.ca/sites/default/files/syphilis_bccfe_guideline-nov2023.pdf
11 Vanbaelen T, Manoharan-Basil SS, Kenyon C. Doxycycline postexposure prophylaxis could induce cross-resistance to other classes of antimicrobials in Neisseria gonorrhoeae: an in silico analysis. Sex Transm Dis 2023; 50(8): 490-3.
| Crossref | Google Scholar | PubMed |
12 National HIV/AIDS Forum 2017. Consensus statement on comprehensive HIV prevention in Aotearoa/New Zealand; 2024. Available at https://hivconsensus.org.nz/
14 The Institute of Environmental Science and Research Ltd. Antimicrobial resistance in Neisseria gonorrhoeae in New Zealand 2023 Surveillance Report Porirua, New Zealand; 2024. Available at https://www.esr.cri.nz/media/qsrcxas3/antimicrobial-resistance-in-neisseria-gonorrhoeae-in-new-zealand-surveillance-report-2023.pdf
15 Kohli M, Medland N, Fifer H, Saunders J. BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections. Sex Transm Infect 2022; 98(3): 235-236.
| Crossref | Google Scholar |
